Physician profile
Stephen Oishi
NPI 1194813832
$7,133.96
in general payments reported to CMS, 2019-2025
27 companies · $32.27 in 2025
The $32.27 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,177 · 2020: $1,342 · 2021: $1,444 · 2022: $656 · 2023: $401 · 2024: $81.66 · 2025: $32.27.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $463 · Education: $51.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $463.08 |
| Education | $51.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $1,160.39 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $831.30 | 2019-2024 | Farxiga, Breztri, Wainua |
| Lilly USA, LLC | $752.12 | 2019-2023 | Mounjaro, Trulicity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $579.01 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $577.81 | 2019-2022 | |
| Abbvie INC. | $423.68 | 2019-2022 | |
| Novo Nordisk INC | $378.27 | 2019-2025 | Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $273.02 | 2019-2021 | |
| Amgen INC. | $259.84 | 2019 | |
| Novartis Pharmaceuticals Corporation | $215.53 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $213.23 | 2019 | |
| Astellas Pharma US INC | $176.53 | 2019 | |
| Sarepta Therapeutics, INC. | $146.67 | 2019-2020 | |
| Radius Health, INC. | $139.04 | 2019-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $130.46 | 2023 | Lifevest |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $125.00 | 2019 | |
| Horizon Therapeutics Plc | $124.99 | 2019 | |
| Sunovion Pharmaceuticals INC. | $124.71 | 2019 | |
| Heron Therapeutics, INC. | $121.85 | 2021 | |
| Allergan, INC. | $112.26 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $91.75 | 2021-2024 | |
| Pfizer INC. | $60.76 | 2019-2020 | |
| Abbott Laboratories | $51.22 | 2021-2022 | |
| Esperion Therapeutics, INC. | $23.30 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $16.81 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $12.45 | 2019 | |
| Biogen, INC. | $11.96 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Oishi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.